Skip to main content
Equibles
ZBIO logo

ZBIO · Zenas BioPharma, Inc.

Track ZBIO — free

Use ZBIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZBIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$26.99 -0.27 (-0.99%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.78B
Shares
65.18M
Volume · Oct 12 5894 Avg daily vol (3M) 728.69K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$27.26 Open$26.18 Day$26.18–27.64 52W close$15.20–43.17 Avg vol 30d677K Short int11.9M · 18.3% float · 15.5d Short vol82% Last earningsJan 5, 2026 DataSep 2024–Oct 2026 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.00M
Trailing 12 months
Net income (TTM)
−$484.38M
Trailing 12 months
Revenue growth YoY
+100.0%
Year over year
Operating margin
-3,830.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-12.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+50.8%
Year over year · more shares
Price change (1Y)
-1.8%
Trailing year
Short interest
18.3%
Latest settlement · 15.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +9%
above
Price vs 50-day avg −11%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 43%
mid-range
Momentum
relative strength
Neutral
1-month return −12%
trailing
6-month return +30%
trailing
YTD return −25%
this year
Relative strength +21%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $31 › 200d $25 — 50d above 200d
Institutional flow Accumulating
3 of 146 funds reported for Sep 30 · net +103 sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
18.32% of float · ▲ +0.6% MoM · 15.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
146 holders — near 2-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Strong
Revenue growth +100%
Y/Y
EPS growth +29%
Y/Y
Free cash flow $-172.4M
Quant / Vol
risk profile
Very High
Volatility 102%
annualized · 1-yr
Max drawdown −65%
past year
ATR 7.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+9% Bullish
Price vs 50-day avg
−11% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
43% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $31 › 200d $25 — 50d above 200d
Institutional flow Accumulating
3 of 146 funds reported for Sep 30 · net +103 sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
18.32% of float · ▲ +0.6% MoM · 15.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
146 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $15 Now $27 · 43% Range high $43
vs 200-day avg +9% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ZBIO
Zenas BioPharma, Inc.
this stock
$1.78B -24.9% +100.0% — 18.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $129.29B +12.5% +46.2% 29.7 1.8%
MRNA
Moderna, Inc.
 $89.83B +663.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.86B -3.3% +20.8% 18.5 2.1%
CSLLY
Csl Ltd
 $61.83B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
147
% held
94.5%
Reported
3 of 146
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
175
View
Short & Settlement
Short Interest Rising
Shares short
11.9M
Days to cover
15.5d
Change
+70.3K sh
View
Short Volume
Short vol %
82%
As of
Oct 9, 2026
Short Total
View
Fails to Deliver
FTD shares
427
Value
$14.0K
As of
Sep 8, 2026
View
Off-Exchange
Off-exchange %
41.1%
Week of
Sep 7, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$10.0M
Net income (FY)
$-377.7M
EPS diluted
$-8.44
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 29, 2026
This year
13
View
Exempt Offerings
Offering
$200.1M
Filed
May 14, 2024
View
Earnings & Events
Webcasts
Last webcast
Sep 29, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
ZBIO -3.7% -12.4% +30.4% +1.1% -24.9%
SPY +1.2% +1.9% +9.9% +2.1% +14.2%
vs SPY -4.8% -14.3% +20.6% -1.0% -39.1%
Key facts CIK 1953926 CUSIP 98937L105 13F (30d) 4 filings 4 filers Visit website Investor relations